Actively Recruiting
Phase I Study Evaluating Safety, Tolerability, and Pharmacokinetics of SHR-4685 in Adults With Advanced Solid Tumors
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-10-05
170
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and pharmacokinetics of SHR-4685 in adults with advanced solid tumors. This phase I study aims to determine the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of SHR-4685, helping to understand how the drug behaves in the body and its potential side effects. Participants will receive SHR-4685 in varying doses as part of a single treatment group. The study monitors participants for up to 24 months to assess adverse events, serious adverse events, and drug concentration levels in plasma. The treatment period includes regular assessments at predefined intervals to gather detailed pharmacokinetic data and observe tumor response measures. During the study, participants will undergo evaluations including tumor measurements based on RECIST 1.1 criteria, laboratory tests to monitor organ function and presence of antibodies against SHR-4685, and safety assessments to track side effects. Researchers will measure outcomes such as objective response rate, disease control rate, duration of response, and progression-free survival. Safety monitoring continues for 30 days after the last dose, and the total participation can last up to two years.
CONDITIONS
Brief Title
A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors
Research Team
R
Ran Zhao, M.D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here